Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

by Xiaoyan Lu, Caitlin Smare, Chrispin Kambili et al.
BMC Health Services Research, 2017 17:87 – Published: 26 January 2017

12 pp. 686 kB
http://bmchealthservres.biomedcentral.com/track/pdf/10.1186/s12913-016-1931-3?
site=bmchealthservres.biomedcentral.com

Less than one-third of patients who are estimated to be infected with multidrug-resistant tuberculosis (MDR-TB) receive MDR-TB treatment regimens, and only 48% of those who received treatment have successful outcomes. Despite current regimens, newer, more effective and cost-effective approaches to treatment are needed. The aim of the study was to project health outcomes and impact on healthcare resources of adding bedaquiline to the treatment regimen of MDR-TB in selected high burden countries: Estonia, Russia, South Africa, Peru, China, the Philippines, and India. The authors conclude that adding bedaquiline to the background regimen provides improvements in health outcomes and reductions in healthcare costs in high MDR-TB burden countries. The range of prices per regimen for which bedaquiline would be cost-effective varied between countries.

(Visited 13 times, 1 visits today)
This entry was posted in Essential Medicines, General, Tuberculosis. Bookmark the permalink.